Azithromycin, levofloxacin up cardiac risk in study of veterans

March 31, 2014
Azithromycin, levofloxacin up cardiac risk in study of veterans

(HealthDay)—Use of azithromycin or levofloxacin is associated with increased risks of death and cardiac arrhythmia compared with amoxicillin use, according to a study published in the March/April issue of the Annals of Family Medicine.

Gowtham A. Rao, M.D., Ph.D., M.P.H., from the University of South Carolina in Columbia, and colleagues conducted a to compare the risk of cardiovascular death and among U.S. veterans taking azithromycin or versus . Participants included veterans (mean age, 56.8 years) who received an exclusive outpatient dispensation for amoxicillin (979,380 ), azithromycin (594,792 patients), or levofloxacin (201,798 patients) between September 1999 and April 2012. Azithromycin was mainly dispensed for five days, while amoxicillin and levofloxacin were usually dispensed for 10 days or longer.

The researchers found that, compared with patients receiving amoxicillin, the risks of death and serious arrhythmia were significantly increased for patients receiving azithromycin (hazard ratios, 1.48 and 1.77, respectively) during days one to five, but the risks were not significantly different on treatment days six to 10. An increased risk of death and serious cardiac arrhythmia was seen for patients receiving levofloxacin versus amoxicillin for days one to five (hazard ratios, 2.49 and 2.43, respectively). For both death and arrhythmia, the risks remained significantly elevated for days six to 10 (hazard ratios, 1.95 and 1.75, respectively).

"There are usually multiple antibiotic choices available for older patients, especially those with cardiac comorbidities; physicians may consider prescribing medications other than azithromycin and levofloxacin," the authors write.

Explore further: Study finds common antibiotic azithromycin carries heart risk

More information: Abstract
Full Text

Related Stories

Azithromycin not tied to increased risk of CV death

May 2, 2013

(HealthDay)—The widely used antibiotic azithromycin (Zithromax or Zmax)—under scrutiny recently because it may increase the risk of death for those with existing heart disease—appears to be safe for young and middle-aged ...

Nocturnal respiratory rate predicts cardiac risk after MI

March 10, 2014

(HealthDay)—Among survivors of acute myocardial infarction (MI), nocturnal respiratory rate (NRR) is significantly associated with cardiac mortality, particularly non-sudden cardiac death, according to research published ...

Recommended for you

No new heart muscle cells in mice after the newborn period

November 5, 2015

A new study from Sweden's Karolinska Institutet shows that new heart muscle cells in mice are mainly formed directly after birth. After the neonatal period the number of heart muscle cells does not change, and A new study ...

Nanotechnology could spur new heart treatment

October 29, 2015

A new nanoparticle developed by University of Michigan researchers could be the key to a targeted therapy for cardiac arrhythmia, a condition that causes the heart to beat erratically and can lead to heart attack and stroke.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.